News & Media

RAS pathway-driven cancers—such as low-grade serous ovarian cancer and KRAS-mutant non-small cell lung cancer—are difficult to treat. For patients with these forms of cancer, currently available treatments face resistance mechanisms and aren’t effective and often have side effects that make them difficult to tolerate. This means patients quickly run out of therapeutic options. At Verastem Oncology, we’re committed to ensuring options exist. For more information about the work we’re doing at Verastem Oncology, please access our Resources section or contact Julissa Viana via email at media@verastem.com.

Press Releases

All Verastem Oncology "Press Releases" are archived here.

Media Resources

Headquartered in Needham, MA, Verastem Oncology Inc. (NASDAQ: VSTM), is a biopharmaceutical company focused on bringing better treatment options to patients who are battling RAS pathway-driven cancers. These types of cancers—which include low-grade serous ovarian cancer and KRAS-mutant non-small cell lung cancer—are extremely difficult to treat and currently available therapeutic options are limited and suboptimal. That’s why new options are needed, and we’re committed to delivering them.

 

For media interested in Verastem Oncology, please contact Julissa Viana via email at media@verastem.com. You can also refer to the resources below, which contain information about what we do, our leadership team and our financials.

 

 

To stay updated on the latest news about Verastem Oncology, sign up for alerts.

Previous and Upcoming Events

Below are past or scheduled upcoming events either hosted or sponsored by Verastem Oncology.

VSTM LGSOC Program Update

01/24/2023 6:00 PM (EST)

B. Riley Oncology Conference

01/28/2022 9:30 AM (EST)

Cantor Virtual Global Healthcare

09/17/2020 3:20 PM (EDT)

Verastem Oncology Conference Call

02/28/2020 8:00 AM (EST)

Verastem Oncology Conference Call

01/08/2020 4:00 PM (EST)

Articles Featuring Verastem Oncology

Contact

Julissa Viana
Investor Relations
media@verastem.com

Tweets by @VerastemOncolog

87% of surveyed patients w/ #LGSOC fear making long-term plans. Results from #LGSOCPatientImpactSurvey at #SGOmtg highlight the impact of LGSOC on patients' lives and the need for comprehensive support and treatment.

https://bit.ly/3IIgM2m

#PowerofSharedPurpose

Attending @SGO_Org's Annual Meeting on Women's Cancer? Stop by our Booth 420 to learn more about our pipeline and advancements in #lowgradeserous #ovariancancer or #LGSOC.

#SGOMtg #PowerofSharedPurpose

4